Anti- or pro-proliferation – Conditional options for TGF-α and cetuximab in head and neck squamous cell carcinoma
- 1 January 2015
- journal article
- Published by Elsevier in Oral Oncology
- Vol. 51 (1) , 46-52
Abstract
No abstract availableKeywords
Funding Information
- Swedish Cancer Society
- National Health Service in Sweden
- Mrs. Berta Kamprad’s Foundation
- The Crafoord Foundation
- Laryng Foundation
This publication has 25 references indexed in Scilit:
- Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck CancerPLOS ONE, 2012
- Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell linesJournal of Cancer Research and Clinical Oncology, 2011
- High- and Low-Affinity Epidermal Growth Factor Receptor-Ligand Interactions Activate Distinct Signaling PathwaysPLOS ONE, 2011
- Coomassie Staining as Loading Control in Western Blot AnalysisJournal of Proteome Research, 2010
- Understanding resistance to EGFR inhibitors—impact on future treatment strategiesNature Reviews Clinical Oncology, 2010
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell linesJournal of Cancer Research and Clinical Oncology, 2008
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating systemProceedings of the National Academy of Sciences, 2008
- Consumption of EGF by A431 cells: evidence for receptor recycling.Journal of Cell Biology, 1993